Preliminary Agenda
Chair: Michal Lotem, Jerusalem, Israel
TBD
Claudio Sette
Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Rome, Italy
A novel splice site polymorphism-guided adoptive immunotherapy for hematologic malignancies
Andrei Thomas-Tikhonenko
Director of Experimental Pathology, Children’s Hospital of Philadelphia, USA
Chair: Caroline Robert, Paris, France
RNA quality control through m6A modification
Julian König
Chair of Biochemistry and RNA-Biology, Theodor-Boveri-Institute, Julius Maximilian University of Würzburg, Germany
TBD
Michal Lotem
Head of the Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, Jerusalem, Israel
Chair: Aron Popovtzer, Jerusalem, Israel
Discovery of a new class of RNA-binding proteins
Matthias W. Hentze
Director, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
GC content as a major determinant of RNA splicing
Xavier Roca
Associate Professor, School of Biological Sciences, Nanyang Technological University Singapore, Singapore
TBD
WuxiApptec
Chair: Rotem Karni, Pennsylvania, USA
When Mis-Translation Meets Immunotherapy
Reuven Agami
Head, Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, The Netherlands
Mechanistic insights of RNA toxicity and disrupted RNA processing from modeling Myotonic Dystrophy in mice
Thomas A. Cooper
S. Donald Greenberg and R. Clarence and Irene H. Fulbright Professor, Department of Pathology and Immunology, Baylor College of Medicine, Dallas, USA
Rethinking mechanisms of mRNA vaccine immunity
Brian D. Brown
Director, Icahn Genomics Institute; Vice Chair, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York City, USA
Chair: Matthias W. Hentze, Germany
RIBOncology: Harnessing cancer genomics for (non-coding) RNA biology and therapeutics
Rory Johnson
Associate Professor, Laboratory for Genomics of Long Noncoding RNA and Disease, University College Dublin, Ireland
Manipulating leukocytes function with RNAs via targeted lipid nanoparticles: From concept to the clinic
Dan Peer
Director of the Laboratory of Precision NanoMedicine and Vice President for Research, Tel Aviv University (TAU), Israel
From ASO design to delivery: The TechNOA platform applied to Urea Cycle Disorders (UCD)
Ernesto Guccione
Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai, New York City, USA
Chair: Ernesto Guccione, New York City, USA
From jumping genes to RNA therapeutics: Retrotransposons in the tumor microenvironment
Beatrice Bodega
Principal Investigator, Professor of Molecular Biology, Co-Founder and Consultant, T-One Therapeutics, INGM and University of Milan, Italy
TBD
Caroline Robert
Head, Dermatology, Director of the Adaptive Resistance Team, Gustave Roussy and Paris Saclay University, Paris, France
Crossing the BBB: Delivering RNA Therapeutics for CNS Disorders
Saul Martinez Montero
Executive Director, RNA Therapeutics, Dyne Therapeutics, Waltham, USA
Chair: Claudio Sette, Rome, Italy
Mapping, Functional Characterization
Danny Incarnato
Associate Professor of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen,
The Netherlands
Moderator: J&J and Merck
Panel TBD
Chair: Rotem Karni, Pennsylvania, USA
Chair: Matthias W. Hentze, Heidelberg, Germany
HNRNPH2-Related Neurodevelopmental Disorder: From Molecular Mechanisms to RNA-Based Therapeutics
Rotem Karni
Principal Investigator, Perelman School of Medicine, University of Pennsylvania, USA
Turning junk into gems: Long non-coding RNAs unlock new therapeutic horizons
Alessandro Bonetti
Director, Early Respiratory, AstraZeneca, Cambridge, UK
The roles of protein-RNA feedback in cellular homeostasis
Jernej Ule
Centre Director and Professor of Neurodegeneration Research; Francis Crick Institute and King’s College London, UK
Chair: Caroline Robert, Paris, France
Decoding the RNA-Binding Protein Network in Muscle Fiber Formation: Implications for Health and Disease
Imed Gallouzi
Professor, Bioscience Chair, Center of Excellence for Smart Health Biomedical Sciences, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia
Precision RNA Strategies to Disrupt Fusion Oncogenes
Kathy Liu
Principal Investigator, Associate Professor, Department of Biochemistry & Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
TBD
Stefan Engelhardt
Director, Institute of Pharmacology and Toxicology, Technical University of Munich (TUM), Germany
Chair: Michal Lotem, Jerusalem, Israel
TBD
Matthew White
Senior Research Fellow, Principal Investigator, King’s College London, UK
Biological activity and regulation of the Nonsense-mediated decay (NMD) pathway
Javier F. Caceres
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK
SNORD81 regulates translation via the multisynthetase complex
Carsten Müller-Tidow
Director of Internal Medicine, Hematology, Oncology, Rheumatology, Heidelberg University Hospital, Germany
